The University of Sheffield
Evaluating the cost effectiveness of the addition 2011 RAFIA.pdf (107.38 kB)

Evaluating the cost-effectiveness of the addition of rituximab to chemotherapy in the first-line treatment of Follicular Lymphoma patients in the UK

Download (107.38 kB)
posted on 2020-02-25, 10:35 authored by Rachid Rafia, Diana PapaioannouDiana Papaioannou, Matthew StevensonMatthew Stevenson, J. Rathbone, Helen Buckley Woods
INTRODUCTION Follicular lymphoma (FL), a clinical subtype of Non-Hodgkin’s lymphoma (NHL) , develops slowly and often without symptoms for many years. In 2008, the incidence of FL in England and Wales was 3.4 per 100,000 persons. Over 70% of FLs are diagnosed in persons aged over 60 years, and 85-90% present with advanced disease, which is defined as lymph nodes on both sides of the diaphragm being involved (stage III) or disease is disseminated with one or more extra-lymphatic organs involved (stage IV). Advanced FL is not curable, thus the aim of disease management is to both increase patient life expectancy and to increase patient health-related quality of life. The objective of this study is to assess, from a UK NHS perspective, the cost-effectiveness of the addition of rituximab (R) to selected chemotherapies: CVP (cyclophosphamide, vincristine and prednisolone); CHOP (cyclophosphamide, doxorubicin, vincristine and prednisolone) and MCP (mitoxantrone, chlorambucil and prednisolone) in the first-line treatment of follicular lymphoma.



  • There is no personal data or any that requires ethical approval


  • The data complies with the institution and funders' policies on access and sharing

Sharing and access restrictions

  • The data can be shared openly

Data description

  • The file formats are open or commonly used

Methodology, headings and units

  • Headings and units are explained in the files

Usage metrics

    School of Health and Related Research - HEDS



    Ref. manager